HB 918·LA·house
PHARMACIES: Provides relative to pharmaceutical costs (OR +$153,127 GF EX See Note)
In CommitteeFiled Feb 27, 2026
Sponsor: Jay Gallé (R)
Latest Action
Read by title, under the rules, referred to the Committee on Health and Welfare.
Mar 9, 2026
Summary
The bill directs the Louisiana Department of Health to develop a list of critical prescription drugs and to require manufacturers of those drugs to report detailed cost, research, and pricing information. The information is kept confidential, used for an annual report to the legislature, and must be included in marketing materials to providers, with the goal of increasing transparency and lowering drug prices.
AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.
Topics
Track this bill
Get real-time alerts when HB 918 changes status, plus AI-powered summaries and stage predictions.
Sign up free